History of myeloid-derived suppressor cells

Nature Reviews Cancer

Volumn 13, Issue 10, 2013, Pages 739-752

  Talmadge, James E ^a   Gabrilovich, Dmitry I ^b  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^b WISTAR INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARGINASE; CD11B ANTIGEN; CD33 ANTIGEN; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 4 RECEPTOR ALPHA; LYMPHOCYTE ANTIGEN;

ANTIBODY PRODUCTION; ANTIGEN EXPRESSION; BONE MARROW CELL; CANCER GROWTH; CELL LINEAGE; CELL PROLIFERATION; DENDRITIC CELL; GENE EXPRESSION; GRANULOCYTE; GRANULOCYTOSIS; HEMATOPOIETIC STEM CELL; HUMAN; LEUKEMOID REACTION; LYMPHOCYTOPENIA; MACROPHAGE; MONOCYTE; MYELOID DERIVED SUPPRESSOR CELL; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; REGULATORY MECHANISM; REVIEW; STEM CELL MOBILIZATION; SUPPRESSOR CELL; T LYMPHOCYTE; TUMOR ESCAPE; TUMOR MICROENVIRONMENT;

ANIMALS; ANTIGENS, DIFFERENTIATION; ANTIGENS, NEOPLASM; CELL BIOLOGY; CELL DIFFERENTIATION; CELL LINEAGE; CHEMOKINES; HEMATOPOIESIS, EXTRAMEDULLARY; HEMATOPOIETIC STEM CELL MOBILIZATION; HISTORY, 20TH CENTURY; HISTORY, 21ST CENTURY; HUMANS; LEUKEMOID REACTION; MEDICAL ONCOLOGY; MICE; MOLECULAR TARGETED THERAPY; MULTIPOTENT STEM CELLS; MYELOID CELLS; MYELOID PROGENITOR CELLS; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; TUMOR BURDEN; TUMOR ESCAPE; TUMOR MICROENVIRONMENT;

EID: 84884556145     PISSN: 1474175X     EISSN: 14741768     Source Type: Journal    
DOI: 10.1038/nrc3581     Document Type: Review

References (193)

1. Sonnenfeld, A. Leukamische reaktiones bei carcinoma. Zeitschrift f Klin Med 111, 108 (in German) (1929).
2. Robinson, W. A. Granulocytosis in Neoplasia. Ann. NY Acad. Sci. 230, 212-218 (1965).
3. Bennett, J. A., Rao, V. S. & Mitchell, M. S. Systemic bacillus Calmette-Guerin (BCG) activates natural suppressor cells. Proc. Natl Acad. Sci. USA 75, 5142-5144 (1978).
4. Slavin, S. & Strober, S. Induction of allograft tolerance after total lymphoid irradiation (TLI): development of suppressor cells of the mixed leukocyte reaction (MLR) J. Immunol. 123, 942-946 (1979).
5. Duwe, A. K. & Singhal, S. K. The immunoregulatory role of bone marrow. I. Suppression of the induction of antibody responses to T-dependent and T-independent antigens by cells in the bone marrow Cell. Immunol. 43, 362-371 (1979).
6. Brooks-Kaiser, J. C., Bourque, L. A. & Hoskin, D. W. Heterogeneity of splenic natural suppressor cells induced in mice by treatment with cyclophosphamide. Immunopharm. 25, 117-129 (1993).
7. Fidler, I. J. Tumor heterogeneity and the biology of cancer invasion and metastasis. Cancer Res. 38, 2651-2660 (1978).
8. Porembka, M. R. et al. Pancreatic adenocarcinoma induces bone marrow mobilization of myeloid-derived suppressor cells which promote primary tumor growth. Cancer Immunol. Immunother. 61, 1373-1385 (2012).
9. Wang, L. et al. Increased myeloid-derived suppressor cells in gastric cancer correlate with cancer stage and plasma S100A8/A9 proinflammatory proteins. J. Immunol. 190, 794-804 (2013).
10. Diaz-Montero, C. M. et al. Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin-cyclophosphamide chemotherapy. Cancer Immunol. Immunother. 58, 49-59 (2009).
11. Younos, I. H., Dafferner, A. J., Gulen, D., Britton, H. C. & Talmadge, J. E. Tumor regulation of myeloid-derived suppressor cell proliferation and trafficking. Int. Immunopharmacol. 13, 245-256 (2012).
12. Donkor, M. K. et al. Mammary tumor heterogeneity in the expansion of myeloid-derived suppressor cells. Int. Immunopharmacol. 9, 937-948 (2009).
13. Rashid, O. M. et al. Resection of the primary tumor improves survival in metastatic breast cancer by reducing overall tumor burden. Surg. 153, 771-778 (2013).
14. Salvadori, S., Martinelli, G. & Zier, K. Resection of solid tumors reverses T cell defects and restores protective immunity. J. Immunol. 164, 2214-2220 (2000).
15. Bayne, L. J. et al. Tumor-derived granulocyte-macrophage colony-stimulating factor regulates myeloid inflammation and T cell immunity in pancreatic cancer. Cancer Cell 21, 822-835 (2012).
16. Younos, I. et al. Tumor-and organ-dependent infiltration by myeloid-derived suppressor cells. Int. Immunopharmacol. 11, 814-826 (2011).
17. Dolcetti, L. et al. Hierarchy of immunosuppressive strength among myeloid-derived suppressor cell subsets is determined by GM-CSF. Eur. J. Immunol. 40, 22-35 (2010).
18. Waight, J. D., Hu, Q., Miller, A., Liu, S. & Abrams, S. I. Tumor-Derived, G.-C. S. F. Facilitates neoplastic growth through a granulocytic myeloid-derived suppressor cell-dependent mechanism. PLoS ONE 6, e27690 (2011).
19. Kowanetz, M. et al. Granulocyte-colony stimulating factor promotes lung metastasis through mobilization of Ly6G+Ly6C+ granulocytes. Proc. Natl Acad. Sci. USA 107, 21248-21255 (2010).
20. Pekarek, L. A., Starr, B. A., Toledano, A. Y. & Schreiber, H. Inhibition of tumor growth by elimination of granulocytes. J. Exp. Med. 181, 435-440 (1995).
21. Li, H., Han, Y., Guo, Q., Zhang, M. & Cao, X. Cancer-Expanded Myeloid-Derived Suppressor Cells Induce Anergy of NK Cells through Membrane-Bound TGF-{beta}1. J. Immunol. 182, 240-249 (2009).
22. Abe, F. et al. Myeloid-derived suppressor cells in mammary tumor progression in FVB Neu transgenic mice. Cancer Immunol. Immunother. 59, 47-62 (2010).
23. Lappat, E. J. & Cawein, M. A. Study of the Leukemoid Response to Transplantable a-280 Tumor in Mice. Cancer Res. 24, 302-311 (1964).
24. Lee, M. Y. & Rosse, C. Depletion of lymphocyte subpopulations in primary and secondary lymphoid organs of mice by a transplanted granulocytosis-inducing mammary carcinoma. Cancer Res. 42, 1255-1260 (1982).
25. Tsuchiya, Y., Igarashi, M., Suzuki, R. & Kumagai, K. Production of colony-stimulating factor by tumor cells and the factor-mediated induction of suppressor cells. J. Immunol. 141, 699-708 (1988).
26. Bennett, J. A. & Mitchell, M. S. Induction of suppressor cells by intravenous administration of Bacillus Calmette-Guerin and its modulation by cyclophosphamide. Biochem. Pharmacol. 28, 1947-1952 (1979).
27. Wren, S. M., Wepsic, H. T., Larson, C. H., De Silva, M. A. & Mizushima, Y. Inhibition of the graft-versus-host response by BCGcw-induced suppressor cells or prostaglandin E1. Cell. Immunol. 76, 361-371 (1983).
28. Predina, J. D. et al. Cytoreduction surgery reduces systemic myeloid suppressor cell populations and restores intratumoral immunotherapy effectiveness. J. Hematol. Oncol. 5, 34 (2012).
29. Delano, M. J. et al. MyD88-dependent expansion of an immature GR-1(+)CD11b(+) population induces T cell suppression and Th2 polarization in sepsis. J. Exp. Med. 204, 1463-1474 (2007).
30. Oseroff, A., Okada, S. & Strober, S. Natural suppressor (NS) cells found in the spleen of neonatal mice and adult mice given total lymphoid irradiation (TLI) express the null surface phenotype J. Immunol. 132, 101-110 (1984).
31. Young, M. R. & Wright, M. A. Myelopoiesis-associated immune suppressor cells in mice bearing metastatic Lewis lung carcinoma tumors: Gamma-interferon plus tumor necrosis factor-alpha synergistically reduces immune suppressor and tumor growth-promoting activities of bone marrow cells and diminishes tumor recurrence and metastasis. Cancer Res. 52, 6335-6340 (1992).
32. Kusmartsev, S. A., Li, Y. & Chen, S. H. Gr-1+ myeloid cells derived from tumor-bearing mice inhibit primary T cell activation induced through CD3/CD28 costimulation. J. Immunol. 165, 779-785 (2000).
33. Gabrilovich, D. et al. Vascular endothelial growth factor inhibits the development of dendritic cells and dramatically affects the differentiation of multiple hematopoietic lineages in vivo. Blood 92, 4150-4166 (1998).
34. Watson, G. A., Fu, Y. X. & Lopez, D. M. Splenic macrophages from tumor-bearing mice co-expressing MAC-1 and MAC-2 antigens exert immunoregulatory functions via two distinct mechanisms. J. Leukoc. Biol. 49, 126-138 (1991).
35. Craddock, C. F. et al. Circulating stem cells in mice treated with cyclophosphamide. Blood 80, 264-269 (1992).
36. Sy, M. S., Miller, S. D. & Claman, H. N. Immune suppression with supraoptimal doses of antigen in contact sensitivity. I. Demonstration of suppressor cells and their sensitivity to cyclophosphamide. J. Immunol. 119, 240-244 (1977).
37. Hooper, D. C., Hoskin, D. W., Gronvik, K. O. & Murgita, R. A. Murine neonatal spleen contains natural T and non-T suppressor cells capable of inhibiting adult alloreactive and newborn autoreactive T-cell proliferation. Cell. Immunol. 99, 461-475 (1986).
38. Pak, A. S. et al. Mechanisms of immune suppression in patients with head and neck cancer: presence of CD34(+) cells which suppress immune functions within cancers that secrete granulocyte-macrophage colony-stimulating factor. Clin. Cancer Res. 1, 95-103 (1995).
39. Young, M. R. I., Young, M. E. & Wright, M. A. Stimulation of immune-suppressive bone marrow cells by colony-stimulating factors. Exp. Hematol. 18, 806-811 (1990).
40. Bronte, V. et al. Unopposed production of granulocyte-macrophage colony-stimulating factor by tumors inhibits CD8+ T cell responses by dysregulating antigen-presenting cell maturation. J. Immunol. 162, 5728-5737 (1999).
41. Serafini, P. et al. High-dose granulocyte-macrophage colony-stimulating factor-producing vaccines impair the immune response through the recruitment of myeloid suppressor cells. Cancer Res. 64, 6337-6343 (2004).
42. Shojaei, F. et al. G-CSF-initiated myeloid cell mobilization and angiogenesis mediate tumor refractoriness to anti-VEGF therapy in mouse models. Proc. Natl Acad. Sci. USA 106, 6742-6747 (2009).
43. Talmadge, J. E. Pathways Mediating the Expansion and Immunosuppressive Activity of Myeloid-Derived Suppressor Cells and Their Relevance to Cancer Therapy. Clin. Cancer Res. 13, 5243-5248 (2007).
44. Boutte, A. M., McDonald, W. H., Shyr, Y., Yang, L. & Lin, P. C. Characterization of the MDSC proteome associated with metastatic murine mammary tumors using label-free mass spectrometry and shotgun proteomics. PLoS ONE 6, e22446 (2011).
45. Chornoguz, O. et al. Proteomic pathway analysis reveals inflammation increases myeloid-derived suppressor cell resistance to apoptosis. Mol. Cell Proteomics 10, M110 002980 (2011).
46. Bronte, V., Serafini, P., Apolloni, E. & Zanovello, P. Tumor-induced immune dysfunctions caused by myeloid suppressor cells. J. Immunother. 24, 431-446 (2001).
47. Gabrilovich, D. I., Velders, M. P., Sotomayor, E. M. & Kast, W. M. Mechanism of immune dysfunction in cancer mediated by immature Gr-1+ myeloid cells. J. Immunol. 166, 5398-5406 (2001).
48. Bronte, V. et al. Apoptotic death of CD8+ T lymphocytes after immunization: induction of a suppressive population of Mac-1+/Gr-1+ cells. J. Immunol. 161, 5313-5320 (1998).
49. Young, M. R., Wright, M. A., Matthews, J. P., Malik, I. & Prechel, M. Suppression of T cell proliferation by tumor-induced granulocyte-macrophage progenitor cells producing transforming growth factor-beta and nitric oxide. J. Immunol. 156, 1916-1922 (1996).
50. Gabrilovich, D. I. et al. The Terminology Issue for Myeloid-Derived Suppressor Cells. Cancer Res. 67, 425-425 (2007).
51. Yang, R. & Roden, R. B. S. The Terminology Issue for Myeloid-Derived Suppressor Cells. Cancer Res. 67, 426-426 (2007).
52. Ribechini, E., Greifenberg, V., Sandwick, S. & Lutz, M. B. Subsets, expansion and activation of myeloid-derived suppressor cells. Med. Microbiol. Immunol. 199, 273-281 (2010).
53. Youn, J. I., Nagaraj, S., Collazo, M. & Gabrilovich, D. I. Subsets of myeloid-derived suppressor cells in tumor-bearing mice. J. Immunol. 181, 5791-5802 (2008).
54. Karsunky, H., Merad, M., Cozzio, A., Weissman, I. L. & Manz, M. G. Flt3 ligand regulates dendritic cell development from Flt3+ lymphoid and myeloid-committed progenitors to Flt3+ dendritic cells in vivo. J. Exp. Med. 198, 305-313 (2003).
55. Movahedi, K. et al. Different tumor microenvironments contain functionally distinct subsets of macrophages derived from Ly6C(high) monocytes. Cancer Res. 70, 5728-5739 (2010).
56. Gabrilovich, D. I. & Nagaraj, S. Myeloid-derived suppressor cells as regulators of the immune system. Nature Rev. Immunol. 9, 162-174 (2009).
57. Sawanobori, Y. et al. Chemokine-mediated rapid turnover of myeloid-derived suppressor cells in tumor-bearing mice. Blood 111, 5457-5466 (2008).
58. Virtuoso, L. P. et al. Characterization of iNOS+ Neutrophil-like ring cell in tumor-bearing mice. J. Transl. Med. 10, 152 (2012).
59. Sasmono, R. T. et al. Mouse neutrophilic granulocytes express mRNA encoding the macrophage colony-stimulating factor receptor (CSF-1R) as well as many other macrophage-specific transcripts and can transdifferentiate into macrophages in vitro in response to CSF-1. J. Leukoc. Biol. 82, 111-123 (2007).
60. Movahedi, K. et al. Identification of discrete tumor-induced myeloid-derived suppressor cell subpopulations with distinct T cell-suppressive activity. Blood 111, 4233-4244 (2008).
61. Haile, L. A., Gamrekelashvili, J., Manns, M. P., Korangy, F. & Greten, T. F. CD49d is a new marker for distinct myeloid-derived suppressor cell subpopulations in mice. J. Immunol. 185, 203-210 (2010).
62. Brandau, S., Moses, K. & Lang, S. The kinship of neutrophils and granulocytic myeloid-derived suppressor cells in cancer: Cousins, siblings or twins? Semin. Cancer Biol. 23, 171-182 (2013).
63. Mielcarek, M., Martin, P. J. & Torok-Storb, B. Suppression of alloantigen-induced T-cell proliferation by CD14+ cells derived from granulocyte colony-stimulating factor-mobilized peripheral blood mononuclear cells. Blood 89, 1 629-1634 (1997).
64. Talmadge, J. et al. Immunologic attributes of cytokine mobilized peripheral blood stem cells and recovery following transplantation. Bone Marrow Transplant. 17, 101-109 (1996).
65. Singh, R. K. et al. Fas-FasL-mediated CD4+ T-cell apoptosis following stem cell transplantation. Cancer Res. 59, 3107-3111 (1999).
66. Wanebo, H. J. et al. Indomethacin sensitive suppressor-cell activity in head and neck cancer patients. The role of the adherent mononuclear cell. Cancer 61, 462-474 (1988).
67. Ko, J. S. et al. Sunitinib mediates reversal of myeloid-derived suppressor cell accumulation in renal cell carcinoma patients. Clin. Cancer Res. 15, 2148-2157 (2009).
68. Laoui, D. et al. Mononuclear phagocyte heterogeneity in cancer: different subsets and activation states reaching out at the tumor site. Immunobiology 216, 1192-1202 (2011).
69. Youn, J. I. & Gabrilovich, D. I. The biology of myeloid-derived suppressor cells: the blessing and the curse of morphological and functional heterogeneity. Eur. J. Immunol. 40, 2969-2975 (2010).
70. Lathers, D. M., Clark, J. I., Achille, N. J. & Young, M. R. Phase IB study of 25-hydroxyvitamin D(3) treatment to diminish suppressor cells in head and neck cancer patients. Hum. Immunol. 62, 1282-1293 (2001).
71. Almand, B. et al. Increased production of immature myeloid cells in cancer patients: a mechanism of immunosuppression in cancer. J. Immunol. 166, 678-689 (2001).
72. Zea, A. H. et al. Arginase-producing myeloid suppressor cells in renal cell carcinoma patients: a mechanism of tumor evasion. Cancer Res. 65, 3044-3048 (2005).
73. Poschke, I., Mougiakakos, D., Hansson, J., Masucci, G. V. & Kiessling, R. Immature immunosuppressive CD14+HLA-DR-/low cells in melanoma patients are Stat3hi and overexpress CD80, CD83, and DC-sign. Cancer Res. 70, 4335-4345 (2010).
74. Filipazzi, P. et al. Identification of a new subset of myeloid suppressor cells in peripheral blood of melanoma patients with modulation by a granulocyte-macrophage colony-stimulation factor-based antitumor vaccine. J. Clin. Oncol. 25, 2546-2553 (2007).
75. Rodriguez, P. C. et al. Arginase I-producing myeloid-derived suppressor cells in renal cell carcinoma are a subpopulation of activated granulocytes. Cancer Res. 69, 1553-1560 (2009).
76. Dumitru, C. A., Moses, K., Trellakis, S., Lang, S. & Brandau, S. Neutrophils and granulocytic myeloid-derived suppressor cells: immunophenotyping, cell biology and clinical relevance in human oncology. Cancer Immunol. Immunother. 61, 1155-1167 (2012).
77. Zhao, F. et al. S100A9 a new marker for monocytic human myeloid-derived suppressor cells. Immunology 136, 176-183 (2012).
78. Mantovani, A. & Sica, A. Macrophages, innate immunity and cancer: balance, tolerance, and diversity. Curr. Opin. Immunol. 22, 231-237 (2010).
79. Glasser, L. & Fiederlein, R. L. Functional differentiation of normal human neutrophils. Blood 69, 937-944 (1987).
80. DuPre, S. A. & Hunter, K. W. Jr. Murine mammary carcinoma 4T1 induces a leukemoid reaction with splenomegaly: association with tumor-derived growth factors. Exp. Mol. Pathol. 82, 12-24 (2007).
81. Sica, A. & Bronte, V. Altered macrophage differentiation and immune dysfunction in tumor development. J. Clin. Invest. 117, 1155-1166 (2007).
82. Sade-Feldman, M. et al. Tumor Necrosis Factor-alpha Blocks Differentiation and Enhances Suppressive Activity of Immature Myeloid Cells during Chronic Inflammation. Immunity 38, 541-554 (2013).
83. Cheng, P. et al. Inhibition of dendritic cell differentiation and accumulation of myeloid-derived suppressor cells in cancer is regulated by S100A9 protein. J. Exp. Med. 205, 2235-2249 (2008).
84. Nagaraj, S. & Gabrilovich, D. I. Myeloid-derived suppressor cells in human cancer. Cancer J. 16, 348-353 (2010).
85. Ostrand-Rosenberg, S. & Sinha, P. Myeloid-derived suppressor cells: linking inflammation and cancer. J. Immunol. 182, 4499-4506 (2009).
86. Gibb, D. R., Saleem, S. J., Kang, D. J., Subler, M. A. & Conrad, D. H. ADAM10 overexpression shifts lympho-and myelopoiesis by dysregulating site 2/site 3 cleavage products of Notch. J. Immunol. 186, 4244-4252 (2011).
87. Song, X. et al. CD11b+/Gr-1+ immature myeloid cells mediate suppression of T cells in mice bearing tumors of IL-1beta-secreting cells. J. Immunol. 175, 8200-8208 (2005).
88. Young, M. R., Wright, M. A. & Young, M. E. Antibodies to colony-stimulating factors block Lewis lung carcinoma cell stimulation of immune-suppressive bone marrow cells. Cancer Immunol. Immunother. 33, 146-152 (1991).
89. Liu, Y. et al. MicroRNA-494 is required for the accumulation and functions of tumor-expanded myeloid-derived suppressor cells via targeting of PTEN. J. Immunol. 188, 5500-5510 (2012).
90. Almand, B. et al. Clinical significance of defective dendritic cell differentiation in cancer. Clin. Cancer Res. 6, 1755-1766 (2000).
91. Melani, C. Myeloid cell expansion elicited by the progression of spontaneous mammary carcinomas in c-erbB-2 transgenic BALB/c mice suppresses immune reactivity. Blood 102, 2138-2145 (2003).
92. Pan, P. Y. et al. Reversion of immune tolerance in advanced malignancy: modulation of myeloid-derived suppressor cell development by blockade of stem-cell factor function. Blood 111, 219-228 (2008).
93. Solheim, J. et al. Spleen but not tumor infiltration by dendritic and T cells is increased by intravenous adenovirus-Flt3 ligand injection. Cancer Gene Ther. 14, 364-371 (2007).
94. Morales, J. K., Kmieciak, M., Knutson, K. L., Bear, H. D. & Manjili, M. H. GM-CSF is one of the main breast tumor-derived soluble factors involved in the differentiation of CD11b-Gr1- bone marrow progenitor cells into myeloid-derived suppressor cells. Breast Cancer Res. Treat. 123, 39-49 (2010).
95. Ko, J. S. et al. Direct and differential suppression of myeloid-derived suppressor cell subsets by sunitinib is compartmentally constrained. Cancer Res. 70, 3526-3536 (2010).
96. Priceman, S. J. et al. Targeting distinct tumor-infiltrating myeloid cells by inhibiting CSF-1 receptor: combating tumor evasion of antiangiogenic therapy. Blood 115, 1461-1471 (2010).
97. DeNardo, D. G. et al. Leukocyte Complexity Predicts Breast Cancer Survival and Functionally Regulates Response to Chemotherapy. Cancer Discov. 1, 54-67 (2011).
98. Fricke, I. et al. Vascular endothelial growth factor-trap overcomes defects in dendritic cell differentiation but does not improve antigen-specific immune responses. Clin. Cancer Res. 13, 4840-4848 (2007).
99. Panopoulos, A. D. & Watowich, S. S. Granulocyte colony-stimulating factor: molecular mechanisms of action during steady state and 'emergency' hematopoiesis. Cytokine 42, 277-288 (2008).
100. Rutella, S., Zavala, F., Danese, S., Kared, H. & Leone, G. Granulocyte colony-stimulating factor: a novel mediator of T cell tolerance. J. Immunol. 175, 7085-7091 (2005).
101. Kyo, S., Kanaya, T., Takakura, M. & Inoue, M. A case of cervical cancer with aggressive tumor growth: possible autocrine growth stimulation by G-CSF and Il-6. Gynecol. Oncol. 78, 383-387 (2000).
102. Okazaki, T. et al. Granulocyte colony-stimulating factor promotes tumor angiogenesis via increasing circulating endothelial progenitor cells and Gr1+CD11b+ cells in cancer animal models. Int. Immunol. 18, 1-9 (2006).
103. Bronte, V. & Zanovello, P. Regulation of immune responses by L-arginine metabolism. Nature Rev. Immunol. 5, 641-654 (2005).
104. Peranzoni, E. et al. Myeloid-derived suppressor cell heterogeneity and subset definition. Curr. Opin. Immunol. 22, 238-244 (2010).
105. Young, M. R., Young, M. E. & Wright, M. A. Myelopoiesis-associated suppressor-cell activity in mice with Lewis lung carcinoma tumors: interferon-gamma plus tumor necrosis factor-alpha synergistically reduce suppressor cell activity. Int. J. Cancer 46, 245-250 (1990).
106. Choi, K. L., Maier, T., Holda, J. H. & Claman, H. N. Suppression of cytotoxic T-cell generation by natural suppressor cells from mice with GVHD is partially reversed by indomethacin. Cell. Immunol. 112, 271-278 (1988).
107. Schlecker, E. et al. Tumor-infiltrating monocytic myeloid-derived suppressor cells mediate CCR5-dependent recruitment of regulatory T cells favoring tumor growth. J. Immunol. 189, 5602-5611 (2012).
108. Youn, J. I., Collazo, M., Shalova, I. N., Biswas, S. K. & Gabrilovich, D. I. Characterization of the nature of granulocytic myeloid-derived suppressor cells in tumor-bearing mice. J. Leukoc. Biol. 91, 167-181 (2012).
109. Mirza, N. All-trans-retinoic acid improves differentiation of myeloid cells and immune response in cancer patients. Cancer Res. 66, 9299-9307 (2006).
110. Kusmartsev, S. et al. All-trans-retinoic acid eliminates immature myeloid cells from tumor-bearing mice and improves the effect of vaccination. Cancer Res. 63, 4441-4449 (2003).
111. Young, M. R. I. et al. 1-alpha, 25-dihydroxyvitamin D3 plus gamma-interferon blocks lung tumor production of granulocyte-macrophage colony-stimulating factor and induction of immunosuppressor cells. Cancer Res. 53, 6006-6006 (1993).
112. Sinha, P. et al. Proinflammatory s100 proteins regulate the accumulation of myeloid-derived suppressor cells. J. Immunol. 181, 4666-4675 (2008).
113. Yang, L. et al. Expansion of myeloid immune suppressor Gr+CD11b+ cells in tumor-bearing host directly promotes tumor angiogenesis. Cancer Cell 6, 409-421 (2004).
114. Zon, L. I. Intrinsic and extrinsic control of haematopoietic stem-cell self-renewal. Nature 453, 306-313 (2008).
115. Si, Y., Tsou, C. L., Croft, K. & Charo, I. F. CCR2 mediates hematopoietic stem and progenitor cell trafficking to sites of inflammation in mice. J. Clin. Invest. 120, 1192-1203 (2010).
116. Johns, J. L. & Christopher, M. M. Extramedullary hematopoiesis: a new look at the underlying stem cell niche, theories of development, and occurrence in animals. Vet. Pathol. 49, 508-523 (2012).
117. Pruijt, J. F., Willemze, R. & Fibbe, W. E. Mechanisms underlying hematopoietic stem cell mobilization induced by the CXC chemokine interleukin-8. Curr. Opin. Hematol. 6, 152-158 (1999).
118. Demetri, G. D. & Griffin, J. D. Granulocyte colony-stimulating factor and its receptor. Blood 78, 2791-2808 (1991).
119. Price, T. H., Chatta, G. S. & Dale, D. C. Effect of recombinant granulocyte colony-stimulating factor on neutrophil kinetics in normal young and elderly humans. Blood 88, 335-340 (1996).
120. Nefedova, Y. Regulation of dendritic cell differentiation and antitumor immune response in cancer by pharmacologic-selective inhibition of the janus-activated kinase 2/signal transducers and activators of transcription 3 pathway. Cancer Res. 65, 9525-9535 (2005).
121. Levesque, J. P., Hendy, J., Takamatsu, Y., Simmons, P. J. & Bendall, L. J. Disruption of the CXCR4/CXCL12 chemotactic interaction during hematopoietic stem cell mobilization induced by GCSF or cyclophosphamide. J. Clin. Invest. 111, 187-196 (2003).
122. Lévesque, J.-P. et al. Mobilization by either cyclophosphamide or granulocyte colony-stimulating factor transforms the bone marrow into a highly proteolytic environment. Exp. Hematol. 30, 440-449 (2002).
123. Link, D. C. Neutrophil homeostasis: a new role for stromal cell-derived factor-1. Immunol. Res. 32, 169-178 (2005).
124. Nagasawa, T. et al. Defects of B-cell lymphopoiesis and bone-marrow myelopoiesis in mice lacking the CXC chemokine PBSF/SDF-1. Nature 382, 635-638 (1996).
125. McQuibban, G. A. Matrix metalloproteinase activity Inactivates the CXC chemokine stromal cell-derived factor-1. J. Biol. Chem. 276, 43503-43508 (2001).
126. Luster, A. D., Alon, R. & von Andrian, U. H. Immune cell migration in inflammation: present and future therapeutic targets. Nature Immunol. 6, 1182-1190 (2005).
127. Ueno, T. et al. Significance of macrophage chemoattractant protein-1 in macrophage recruitment, angiogenesis, and survival in human breast cancer. Clin. Cancer Res. 6, 3282-3289 (2000).
128. Watanabe, T. et al. GM-CSF-mobilized peripheral blood CD34+ cells differ from steady-state bone marrow CD34+ cells in adhesion molecule expression. Bone Marrow Transplant. 19, 1175-1181 (1997).
129. Pruijt, J. F. et al. Anti-LFA-1 blocking antibodies prevent mobilization of hematopoietic progenitor cells induced by interleukin-8. Blood 91, 4099-4105 (1998).
130. Jin, H., Su, J., Garmy-Susini, B., Kleeman, J. & Varner, J. Integrin α4β1 promotes monocyte trafficking and angiogenesis in tumors. Cancer Res. 66, 2146-2152 (2006).
131. Jin, H. et al. A homing mechanism for bone marrow-derived progenitor cell recruitment to the neovasculature. J. Clin. Invest. 116, 652-662 (2006).
132. Jin, F. et al. Degradation of BM SDF-1 by MMP-9: the role in G-CSF-induced hematopoietic stem/progenitor cell mobilization. Bone Marrow Transplant 42, 581-588 (2008).
133. Chavakis, E. et al. Role of beta2-integrins for homing and neovascularization capacity of endothelial progenitor cells. J. Exp. Med. 201, 63-72 (2005).
134. Youn, J. I. et al. Epigenetic silencing of retinoblastoma gene regulates pathologic differentiation of myeloid cells in cancer. Nature Immunol. 14, 211-220 (2013).
135. Connolly, M. K. et al. Distinct populations of metastases-enabling myeloid cells expand in the liver of mice harboring invasive and preinvasive intra-abdominal tumor. J. Leukoc. Biol. 87, 713-725 (2010).
136. De Santo, C. Nitroaspirin corrects immune dysfunction in tumor-bearing hosts and promotes tumor eradication by cancer vaccination. Proc. Natl Acad. Sci. 102, 4185-4190 (2005).
137. Ellies, L. G. et al. Mammary tumor latency is increased in mice lacking the inducible nitric oxide synthase. Int. J. Cancer 106, 1-7 (2003).
138. Sun, H. L. et al. Increased frequency and clinical significance of myeloid-derived suppressor cells in human colorectal carcinoma. World J. Gastroenterol. 18, 3303-3309 (2012).
139. Paget, S. The distribution of secondary growths in cancer of the breast. 1889. Cancer Metastasis Rev. 8, 98-101 (1989).
140. Balwit, J. M., Hwu, P., Urba, W. J. & Marincola, F. M. The iSBTc/SITC primer on tumor immunology and biological therapy of cancer: a summary of the 2010 program. J. Transl. Med. 9, 18 (2011).
141. Sumida, K. et al. Anti-IL-6 receptor mAb eliminates myeloid-derived suppressor cells and inhibits tumor growth by enhancing T-cell responses. Eur. J. Immunol. 42, 2060-2072 (2012).
142. Vincent, J. et al. 5-Fluorouracil selectively kills tumor-associated myeloid-derived suppressor cells resulting in enhanced T cell-dependent antitumor immunity. Cancer Res. 70, 3052-3061 (2010).
143. Kodumudi, K. N. et al. A novel chemoimmunomodulating property of docetaxel: suppression of myeloid-derived suppressor cells in tumor bearers. Clin. Cancer Res. 16, 4583-4594 (2010).
144. Serafini, P. et al. Phosphodiesterase-5 inhibition augments endogenous antitumor immunity by reducing myeloid-derived suppressor cell function. J. Exp. Med. 203, 2691-2702 (2006).
145. Suzuki, E. Gemcitabine selectively eliminates splenic Gr-1+/CD11b+ myeloid suppressor cells in tumor-bearing animals and enhances antitumor Immune activity. Clin. Cancer Res. 11, 6713-6721 (2005).
146. Antonia, S. J. et al. Combination of p53 cancer vaccine with chemotherapy in patients with extensive stage small cell lung cancer. Clin. Cancer Res. 12, 878-887 (2006).
147. Mukherjee, P. et al. Progression of pancreatic adenocarcinoma Is significantly impeded with a combination of vaccine and COX-2 inhibition. J. Immunol. 182, 216-224 (2009).
148. Stenvold, H. et al. Overexpression of matrix metalloproteinase-7 and-9 in NSCLC tumor and stromal cells: correlation with a favorable clinical outcome. Lung Cancer 75, 235-241 (2012).
149. Corzo, C. A. et al. HIF-1alpha regulates function and differentiation of myeloid-derived suppressor cells in the tumor microenvironment. J. Exp. Med. 207, 2439-2453 (2010).
150. Du, R. et al. HIF1alpha induces the recruitment of bone marrow-derived vascular modulatory cells to regulate tumor angiogenesis and invasion. Cancer Cell 13, 206-220 (2008).
151. Yang, L. et al. Abrogation of TGF beta signaling in mammary carcinomas recruits Gr-1+CD11b+ myeloid cells that promote metastasis. Cancer Cell 13, 23-35 (2008).
152. Forrester, E. et al. Effect of conditional knockout of the type II TGF-beta receptor gene in mammary epithelia on mammary gland development and polyomavirus middle T antigen induced tumor formation and metastasis. Cancer Res. 65, 2296-2302 (2005).
153. Fidler, I. J. Metastasis: quantitative analysis of distribution and fate of tumor emboli labeled wth 1251-5-lodo-2′-deoxyuridine1,2,3. J. Natl Cancer Inst. 45, 773-782 (1970).
154. Fidler, I. J., Gersten, D. M. & Hart, I. R. The biology of cancer invasion and metastasis. Adv. Cancer Res. 28, 149-250 (1978).
155. Hart, I. R. & Fidler, I. J. Role of organ selectivity in the determination of metastatic patterns of B16 melanoma. Cancer Res. 40, 2281-2287 (1980).
156. Psaila, B. & Lyden, D. The metastatic niche: adapting the foreign soil. Nature Rev. Cancer 9, 285-293 (2009).
157. Kaplan, R. N., Rafii, S. & Lyden, D. Preparing the "Soil": the premetastatic niche. Cancer Res. 66, 11089-11093 (2006).
158. Talmadge, J. E. & Fidler, I. J. AACR centennial series: the biology of cancer metastasis: historical perspective. Cancer Res. 70, 5649-5669 (2010).
159. Nishie, A. et al. Macrophage infiltration and heme oxygenase-1 expression correlate with angiogenesis in human gliomas. Clin. Cancer Res. 5, 1107-1113 (1999).
160. Asahara, T. et al. Isolation of putative progenitor endothelial cells for angiogenesis. Science 275, 964-967 (1997).
161. Mauro, E. et al. Mobilization of endothelial progenitor cells in patients with hematological malignancies after treatment with filgrastim and chemotherapy for autologous transplantation. Eur. J. Haematol. 78, 374-380 (2007).
162. Nolan, D. J. et al. Bone marrow-derived endothelial progenitor cells are a major determinant of nascent tumor neovascularization. Genes Dev. 21, 1546-1558 (2007).
163. Davidoff, A. M. et al. Bone marrow-derived cells contribute to tumor neovasculature and, when modified to express an angiogenesis inhibitor, can restrict tumor growth in mice. Clin. Cancer Res. 7, 2870-2879 (2001).
164. Dome, B. Identification and clinical significance of circulating endothelial progenitor cells in human non-small cell lung cancer. Cancer Res. 66, 7341-7347 (2006).
165. Young, M. R., Kolesiak, K., Wright, M. A. & Gabrilovich, D. I. Chemoattraction of femoral CD34+ progenitor cells by tumor-derived vascular endothelial cell growth factor. Clin. Exp. Metastasis 17, 881-888 (1999).
166. Mulligan, J. K., Rosenzweig, S. A. & Young, M. R. Tumor secretion of VEGF induces endothelial cells to suppress T cell functions through the production of PGE2. J. Immunother. 33, 126-135 (2010).
167. Madlambayan, G. J. et al. Bone marrow stem and progenitor cell contribution to neovasculogenesis is dependent on model system with SDF-1 as a permissive trigger. Blood 114, 4310-4319 (2009).
168. Li, B. et al. Low levels of tumor necrosis factor alpha increase tumor growth by inducing an endothelial phenotype of monocytes recruited to the tumor site. Cancer Res. 69, 338-348 (2009).
169. Asahara, T. et al. VEGF contributes to postnatal neovascularization by mobilizing bone marrow-derived endothelial progenitor cells. EMBO J. 18, 3964-3972 (1999).
170. Lyden, D. et al. Impaired recruitment of bone-marrow-derived endothelial and hematopoietic precursor cells blocks tumor angiogenesis and growth. Nature Med. 7, 1194-1201 (2001).
171. Whiteside, T. L. The tumor microenvironment and its role in promoting tumor growth. Oncogene 27, 5904-5912 (2008).
172. Whiteside, T. L. Tricks tumors use to escape from immune control. Oral Oncol. 45, e119-e123 (2009).
173. Montero, A. J., Diaz-Montero, C. M., Kyriakopoulos, C. E., Bronte, V. & Mandruzzato, S. Myeloid-derived suppressor cells in cancer patients: a clinical perspective. J. Immunother. 35, 107-115 (2012).
174. Poschke, I. & Kiessling, R. On the armament and appearances of human myeloid-derived suppressor cells. Clin. Immunol. 144, 250-268 (2012).
175. Joyce, J. A. & Pollard, J. W. Microenvironmental regulation of metastasis. Nature Rev. Cancer 9, 239-252 (2009).
176. Mazzoni, A. et al. Myeloid suppressor lines inhibit T cell responses by an NO-dependent mechanism. J. Immunol. 168, 689-695 (2002).
177. Rodriguez, P. C. et al. Arginase I production in the tumor microenvironment by mature myeloid cells inhibits T-cell receptor expression and antigen-specific T-cell responses. Cancer Res. 64, 5839-5849 (2004).
178. Nagaraj, S., Schrum, A. G., Cho, H. I., Celis, E. & Gabrilovich, D. I. Mechanism of T cell tolerance induced by myeloid-derived suppressor cells. J. Immunol. 184, 3106-3116 (2010).
179. Wu, L. et al. Inhibition of PPARgamma in myeloid-lineage cells induces systemic inflammation, immunosuppression, and tumorigenesis. Blood 119, 115-126 (2012).
180. Wolf, A. M. et al. The effect of zoledronic acid on the function and differentiation of myeloid cells. Haematologica 91, 1165-1171 (2006).
181. Talmadge, J. E. et al. Chemoprevention by cyclooxygenase-2 inhibition
182. van Cruijsen, H. et al. Sunitinib-Induced myeloid lineage redistribution in renal cell cancer patients: CD1c+ dendritic cell frequency predicts progression-free survival. Clin. Cancer Res. 14, 5884-5892 (2008).
183. Shojaei, F. et al. Bv8 regulates myeloid-cell-dependent tumour angiogenesis. Nature 450, 825-831 (2007).
184. Huang, D. et al. Interleukin-8 mediates resistance to antiangiogenic agent sunitinib in renal cell carcinoma. Cancer Res. 70, 1063-1071 (2010).
185. Shojaei, F. et al. Tumor refractoriness to anti-VEGF treatment is mediated by CD11b+Gr1+ myeloid cells. Nature Biotechnol. 25, 911-920 (2007).
186. Finke, J. et al. MDSC as a mechanism of tumor escape from sunitinib mediated anti-angiogenic therapy. Int. Immunopharmacol. 11, 856-861 (2011).
187. Carmeliet, P. & Jain, R. K. Molecular mechanisms and clinical applications of angiogenesis. Nature 473, 298-307 (2011).
188. Fischer, C., Mazzone, M., Jonckx, B. & Carmeliet, P. FLT1 and its ligands VEGFB and PlGF: drug targets for anti-angiogenic therapy? Nature Rev. Cancer 8, 942-956 (2008).
189. Xu, L. et al. Direct Evidence that Bevacizumab, an Anti-VEGF Antibody, Up-regulates SDF1α, CXCR4, CXCL6, and Neuropilin 1 in Tumors from Patients with Rectal Cancer. Cancer Res. 69, 7905-7910 (2009).
190. Filipazzi, P., Huber, V. & Rivoltini, L. Phenotype, function and clinical implications of myeloid-derived suppressor cells in cancer patients. Cancer Immunol. Immunother. 61, 255-263 (2012).
191. Greten, T. F., Manns, M. P. & Korangy, F. Myeloid derived suppressor cells in human diseases. Int. Immunopharmacol. 11, 802-807 (2011).
192. Zhang, J., Patel, L. & Pienta, K. J. CC chemokine ligand 2 (CCL2) promotes prostate cancer tumorigenesis and metastasis. Cytokine Growth Factor Rev. 21, 41-48 (2010).
193. Melani, C., Sangaletti, S., Barazzetta, F. M., Werb, Z. & Colombo, M. P. Amino-biphosphonate mediated MMP-9 inhibition breaks the tumor-bone marrow axis responsible for myeloid-derived suppressor cell expansion and macrophage infiltration in tumor stroma. Cancer Res. 67, 11438-11446 (2007).